Diabetes prevention

A post-hoc analysis of the German Prediabetes Lifestyle Intervention Study has found that people who achieve remission of prediabetes by losing weight through lifestyle intervention for 12 months may reduce their risk for developing type 2 diabetes.

Two linked randomized trials published in JAMA support a role for verapamil, but not for intensive glycemic control, to slow C-peptide decline in children with newly diagnosed type 1 diabetes.

Click through to read more on this announcement

Daily treatment with the vitamin D analog eldecalcitol has not prevented the development of type 2 diabetes or promoted a return to normoglycemia in a study of Japanese adults with impaired glucose tolerance.

A pooled analysis of the DAPA-HF and DAPA-CKD trials suggests that taking the SGLT2 inhibitor dapagliflozin reduced the participants’ risk for developing type 2 diabetes by around a third.

Reducing blood pressure may be an effective strategy for the prevention of new-onset type 2 diabetes, suggest researchers from the Blood Pressure Lowering Treatment Trialists’ Collaboration.

UK researchers suggest raising the glycated hemoglobin threshold that is used to identify individuals at high risk for developing type 2 diabetes within 5 years.

A 6-month course of treatment with the tyrosine kinase inhibitor imatinib may slow the decline in beta-cell function in people with newly diagnosed type 1 diabetes, but the effect is not sustained in the longer term, phase 2 study findings indicate.

Children with familial type 1 diabetes have different characteristics to those with sporadic diabetes at presentation, but longer-term outcomes are similar, say researchers.

Phase 2 study results suggest that add-on treatment with an anti-IL-21 antibody plus liraglutide could preserve endogenous insulin secretion in people with recent-onset type 1 diabetes.

Prolonged follow-up of high-risk people treated with teplizumab to prevent progression to type 1 diabetes shows a lasting beneficial effect on beta-cell function, say researchers.

The incidence of diabetes in high- and middle-income countries may at last be stabilizing, or even in decline, say researchers.

Delaying progression from impaired glucose tolerance to type 2 diabetes reduces the risk for micro- and macrovascular complications, shows 24 years of follow-up of the Da Qing trial.

Use of the SGLT2 inhibitor dapagliflozin is associated with a reduced risk for new-onset type 2 diabetes in high-risk individuals with heart failure and reduced ejection fraction, suggests an exploratory analysis of data from the DAPA-HF trial.

Lifestyle intervention significantly reduces the risk for type 2 diabetes in people who have prediabetes based on fasting plasma glucose or glycated hemoglobin measurements, show findings from a randomized trial.

Several therapies aimed at slowing the progression of early type 1 diabetes show promise in research presented at the virtual 80th ADA Scientific Sessions.

Among the latest findings from the DPP Outcomes Study is that long-term use of metformin does not affect the risk for cancer.

The effectiveness of interventions to increase objectively measured physical activity in people at high risk for developing type 2 diabetes declines in line with symptoms of depression within the normal range, say researchers.

A systematic review and meta-analysis published in The BMJ confirms that intake of omega-3 fats does not influence the risk for or progression of type 2 diabetes.

Genetics and dietary fat each influence people’s risk for developing type 2 diabetes, but without any interaction between the two, show the findings of an individual participant data meta-analysis.